Daily CSR

Soleno Therapeutics Lawsuit Over Misleading DCCR Trial Claims

2026-03-23T13:34:00+01:00

The Schall Law Firm, a nationwide firm focused on shareholder rights litigation, is alerting investors to a class action lawsuit filed against Soleno Therapeutics, Inc. (“Soleno” or “the Company”) (NASDAQ: SLNO). The suit alleges violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, along with Rule 10b-5 issued by the U.S. Securities and Exchange Commission.

Investors who acquired the company’s securities between March 26, 2025, and November 4, 2025 (the “Class Period”), are urged to reach out to the firm before May 5, 2026.

You are invited to get in touch with Brian Schall at The Schall Law Firm, located at 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, by calling 310-301-3335 to review your legal rights at no cost. Alternatively, you may connect with the firm through its website at www.schallfirm.com or via email at bschall@schallfirm.com .

The class in this matter has not yet been certified, meaning you are not currently represented by legal counsel. If you decide not to take any action, you may remain an absent member of the class.

The complaint alleges that the Company issued statements to the market that were inaccurate and misleading. It claims that Soleno minimized safety concerns identified during its Phase 3 clinical trial of diazoxide choline extended-release tablets (DCCR). In reality, the treatment was associated with higher safety risks than disclosed, along with reduced commercial potential and an increased likelihood of adverse events. As a result, the Company’s public disclosures were materially misleading throughout the class period. Once these issues became known, investors experienced financial losses.

Click here to Join the case to recover your losses.

Soleno Therapeutics SLNO Securities Fraud Class Action Lawsuit Update

2026-03-18T05:24:00+01:00

Kahn Swick & Foti, LLC (“KSF”), along with its partner and former Louisiana Attorney General, Charles C. Foti, Jr., is alerting investors of Soleno Therapeutics, Inc. (“Soleno” or the “Company”) about a filed securities class action lawsuit.

Class Definition:
The lawsuit aims to recover damages for investors who purchased or held Soleno securities and experienced losses due to alleged securities fraud occurring between March 26, 2025, and November 4, 2025. Additional details are available at
https://www.ksfcounsel.com/cases/nasdaqcm-slno/

Investors who may be affected can reach out to KSF Managing Partner Lewis Kahn at 1-877-515-1850 (toll-free), via email at lewis.kahn@ksfcounsel.com , or by visiting the link above for more information.

Case Summary:
According to the complaint, Soleno and certain executives are accused of withholding important information during the class period, in violation of federal securities laws. The allegations claim that the company made misleading statements and/or failed to disclose key facts, including:

The Phase 3 clinical trials for DCCR—its sole commercial product intended to treat hyperphagia in individuals with Prader-Willi syndrome (PWS)—allegedly downplayed, misrepresented, or omitted significant evidence of safety concerns, including signs of excessive fluid retention in participants.
As a result, the treatment may have posed greater safety risks than what the company disclosed publicly.
Consequently, DCCR’s commercial prospects were potentially overstated, while risks such as adverse side effects, higher discontinuation rates, reduced patient uptake, physician hesitation, possible regulatory challenges, and reputational or legal consequences were not fully revealed.

The case is titled City of Pontiac Police and Fire Retirement System v. Soleno Therapeutics, Inc., No. 26-cv-01979.

Next Steps:
If you invested in Soleno during the specified period and incurred losses, you may apply to be appointed as lead plaintiff by May 5, 2026. However, participation in any potential recovery does not depend on serving in that role.

Navan Investors Alert: Class Action Filed Over Alleged IPO Disclosure Issues

2026-03-16T15:33:00+01:00

Kahn Swick & Foti, LLC (KSF), along with its partner Charles C. Foti Jr., has alerted investors of Navan, Inc about a securities class action lawsuit filed against the company.

Class Definition
The legal action aims to recover losses for investors who purchased Navan shares through or traceable to the Registration Statement and Prospectus (together referred to as the “Offering Documents”) issued for the company’s October 2025 initial public offering (IPO). Individuals seeking additional details or wishing to speak with a member of the legal team can visit: https://www.ksfcounsel.com/cases/nasdaqgs-navn/

Navan investors may also reach out to KSF Managing Partner Lewis Kahn by calling 1-877-515-1850 or emailing lewis.kahn@ksfcounsel.com for further information about the case.

Case Details
The complaint alleges that Navan and certain company executives failed to disclose important information in the Offering Documents, potentially breaching federal securities laws. Specifically, the filing claims that the documents omitted or misrepresented key facts, including a substantial rise in the company’s “sales and marketing” expenses. For the quarter ending October 31, 2025, those costs reportedly climbed to nearly $95 million—an increase of about 39% compared with $68.5 million recorded in the quarter ending July 31, 2025. According to the lawsuit, once this information became public, Navan’s share price dropped significantly.

The case is titled McCown v. Navan, Inc., Case No. 26-cv-01550.

Next Steps for Investors
Investors who bought Navan securities during the relevant period and experienced financial losses have until April 24, 2026 to ask the court to appoint them as the lead plaintiff. Participation in any potential settlement or recovery, however, does not require serving in that role.

Varonis Class Action Lawsuit – Investor Claim & Lead Plaintiff Deadline

2026-01-22T03:53:00+01:00

Why this matters: Rosen Law Firm, an international law firm specializing in investor rights, is alerting individuals who purchased Varonis Systems, Inc. (NASDAQ: VRNS) common stock between February 4, 2025, and October 28, 2025 (inclusive) about the March 9, 2026 deadline to file for lead plaintiff status.

What it means for you: If you acquired Varonis stock during this period, you could be eligible for compensation without any upfront costs, as fees are handled on a contingency basis.

Next steps: To participate in the Varonis class action, submit your information at https://rosenlegal.com/submit-form/?case_id=50337, call Phillip Kim, Esq. toll-free at 866-767-3653, or email case@rosenlegal.com . A lawsuit has already been filed. Those seeking to act as lead plaintiff must petition the Court by March 9, 2026. The lead plaintiff represents all class members and helps guide the litigation.

Why choose Rosen Law Firm: Investors are encouraged to select counsel with proven leadership and experience in securities litigation. Many firms sending notices lack substantial trial experience, resources, or peer recognition and may only refer clients rather than litigate cases themselves. Rosen Law Firm specializes in securities class actions and shareholder derivative lawsuits, representing clients worldwide. The firm achieved the largest-ever securities class action settlement involving a Chinese company at the time, was ranked No. 1 by ISS Securities Class Action Services in 2017 for settlements, has consistently been in the top four since 2013, and has recovered hundreds of millions of dollars for investors. In 2019, it secured over $438 million in recoveries, and founding partner Laurence Rosen was recognized by Law360 as a Titan of the Plaintiffs’ Bar in 2020. Many of the firm’s attorneys have received accolades from Lawdragon and Super Lawyers.

Case details: The lawsuit alleges that Varonis’ leadership made materially false or misleading statements and/or failed to disclose that:

The company could not sustain its annual recurring revenue (ARR) projections while transitioning both federal and non-federal on-premises customers to a software-as-a-service (SaaS) model;
Varonis was unable to convince existing customers to adopt the SaaS solution or retain them on its platform, leading to significantly slower ARR growth in the near term; and
Consequently, prior positive statements about Varonis’ business and prospects were materially misleading or lacked a reasonable basis. When the truth became public, investors allegedly suffered financial losses.

To join the class action, visit https://rosenlegal.com/submit-form/?case_id=50337, call Phillip Kim, Esq. at 866-767-3653, or email case@rosenlegal.com for information.

Important note: No class has been certified yet. Until certification, you are not represented by counsel unless you hire one. You may choose your own attorney or remain an absent class member. Your ability to recover potential future losses does not require serving as lead plaintiff.

Sprouts Farmers Market (SFM) Class Action: Investor Lawsuit & Lead Plaintiff Deadline

2026-01-22T03:50:00+01:00

Important Notice for Sprouts Farmers Market Investors
The Rosen Law Firm, an international firm specializing in investor rights, reminds individuals who purchased Sprouts Farmers Market, Inc. (NASDAQ: SFM) securities or sold put options between June 4, 2025, and October 29, 2025 (inclusive) of the upcoming lead plaintiff deadline on January 26, 2026.

Why this matters: If you bought Sprouts Farmers Market securities or sold put options during this period, you could be eligible for compensation without any upfront costs, thanks to a contingency fee arrangement.

Next steps: To participate in the Sprouts Farmers Market class action, visit https://rosenlegal.com/submit-form/?case_id=48630, call Phillip Kim, Esq. toll-free at 866-767-3653, or email case@rosenlegal.com for more information. A class action lawsuit has already been filed. If you want to be considered for lead plaintiff, you must file with the Court by January 26, 2026. The lead plaintiff represents the interests of all class members and helps guide the litigation.

Why choose Rosen Law Firm: Investors are encouraged to select experienced counsel with a proven record in leadership roles. Many firms issuing notices may not actually litigate securities class actions but act only as intermediaries. Rosen Law Firm focuses exclusively on securities class actions and shareholder derivative litigation, representing clients worldwide. The firm has a history of significant achievements, including securing the largest securities class action settlement against a Chinese company at the time and recovering hundreds of millions of dollars for investors. Rosen Law Firm has been ranked in the top four for settlements since 2013 and was ranked No. 1 by ISS Securities Class Action Services in 2017. In 2019, the firm recovered over $438 million, and founding partner Laurence Rosen was recognized as a Titan of the Plaintiffs’ Bar by Law360 in 2020. Many attorneys at the firm have also been honored by Lawdragon and Super Lawyers.

Case details: The lawsuit alleges that defendants misrepresented Sprouts Farmers Market's growth potential for fiscal year 2025. Statements from the company claimed confidence in the resilience of its customer base despite economic pressures and suggested that Sprouts would benefit from certain favorable market trends. However, the defendants allegedly provided false or misleading information while concealing material adverse facts, including that cautious consumer behavior could slow sales growth and negate expected benefits. When the truth emerged, investors allegedly experienced financial losses.

To participate in the class action, go to https://rosenlegal.com/submit-form/?case_id=48630, call Phillip Kim, Esq. at 866-767-3653, or email case@rosenlegal.com .

Important note: No class has been certified yet. Until certification, you are not represented by counsel unless you hire one. You can choose your own attorney or remain an absent class member. Participation in any future recovery does not depend on serving as lead plaintiff.
Stay connected:

Attorney Advertising. Prior results do not guarantee similar outcomes.
Contact:
Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor, New York, NY 10016
Tel: (212) 686-1060 | Toll-Free: (866) 767-3653 | Fax: (212) 202-3827
Email: case@rosenlegal.com | www.rosenlegal.com